Data on mRNA vaccines sent by Moderna to European regulators before the COVID-19 outbreak included early tests of the mRNA ...

An experimental vaccine for kidney cancer is off to a promising start. In data from a Phase I trial released this week, the ...

As Moderna maps out a more cautious future amid lower-than-expected sales of its current products, the company is bolstering ...

We recently compiled a list of the 10 Firms Fall Amid Disappointing Earnings Performance. In this article, we are going to ...

It has been almost five years since the COVID-19 pandemic happened and close to two years since President Marcos lifted the public health emergency in the country. And yet, costly irregularities, ...

It has been almost five years since the COVID-19 pandemic happened and yet, costly irregularities, shortcomings and missteps surrounding the Duterte era COVID-19 pandemic response continue to rear ...

Kennedy, who has faced opposition from health groups and Democrats, has long sown doubts about the safety and efficacy of ...

We recently compiled a list of the The 10 Worst-Performing Stocks on Monday. In this article, we are going to take a look at ...

While the virus hasn’t made a sustained leap into humans, vaccines and treatments are being developed ahead of an outbreak.

We recently published a list of These 10 Stocks Were Wednesday’s Worst Performers. In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands among Wednesday’s ...

RNA vaccine developer Moderna (MRNA) is sinking 9% after Goldman Sachs downgraded the shares to Neutral from Buy. Why Goldman ...

High vaccine wastage and low vaccination and booster rates marred the government’s P74.68-million COVID-19 National ...